There is abundant evidence that SGLT-2 inhibitors lower patients’ overall risk of myocardial infarction and stroke.6,7 Unlike many other diabetic medications, they improve morbidity and mortality without posing a significant risk of hypoglycemia.8 The global prevalence of these medications will surely increase in the coming years, emphasizing the importance of widespread emergency physician (EP) awareness of eDKA recognition and management. The gene discussed is SLC5A2; the disease is stroke disorder.